Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|November 10, 2015
European Pharma and Biotech Looking Outside EU for Funding
November 10, 2015.
Advertisement
The European Union remains a "powerhouse of innovation" for biotech and pharma, but mostly looks the the US for funding, according to a new report from BioPharm Insight.
Fuelling the growth of EU Pharma and Biotech states that
- Although trials have dropped by 24% since 2010, sector innovation is high, led by innovations in oncology drugs, neurological agents and gene therapy treatments.
- Deal activity is up in 2015 to date, with increasing interest from European investors; however, three out of top five IPOs listed outside the EU.
- Deeper pools of capital and specialist investors are key factors attracting biotech and pharma to US for funding.
- EU biotechs are exploring a wide spectrum of funding opportunities, including crowdfunding, grant funding and secondary listings.
Copies of the report can be obtained by contacting
Advertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Advertisement
Advertisement
Trending on PharmExec
1
ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million
2
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
3
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
4
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
5